This inventor holds 1 USPTO granted patent. Top assignee: Tpo 'Pharmachim'. Active years: 1987.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1987
Title: Georgi L Tanev: Innovator in Biologically Active Esters
Introduction
Georgi L Tanev is a notable inventor based in Sofia, Bulgaria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of biologically active compounds. His work focuses on creating innovative solutions that enhance therapeutic efficacy while minimizing side effects.
Latest Patents
Georgi L Tanev holds a patent for "Esters of O(2,6-dichlorophenylamino) phenylacetic acid." This invention relates to biologically active esters and a method for their preparation. The esters have a specific formula where R represents a hydroxyl group or a radical, and n is an integer ranging from 10 to 450. The molecular mass of these compounds varies from 700 to 30,000, as determined by the vapor pressure method. The compounds are synthesized by reacting O(2,6-dichlorophenylamino) phenylacetic acid with polyethyleneglycols in the presence of an acid and heated in an inactive solvent. These innovative compounds exhibit high antiphlogistic activity while being less irritating to the stomach mucosa compared to prior art compounds.
Career Highlights
Georgi L Tanev is associated with TPO Pharmachim, where he continues to advance his research and development efforts. His work has led to the creation of valuable pharmaceutical products that contribute to improved patient outcomes.
Collaborations
Georgi collaborates with talented individuals such as Orhideya B Zabunova and Hristo B Zvetanov. Their combined expertise fosters a productive environment for innovation and development in the pharmaceutical sector.
Conclusion
Georgi L Tanev's contributions to the field of biologically active esters highlight his commitment to advancing pharmaceutical science. His innovative work continues to pave the way for new therapeutic options that benefit patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile